Ex-Valeant executive, ex-pharmacy CEO charged for fraud scheme
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Additional Charges Against Valeant Pharma (VRX) or Former Execs Cannot Be Ruled Out - Wells Fargo's Maris
November 17, 2016 1:46 PM ESTWells Fargo analyst David Maris weighed in on Valeant Pharma (NYSE: VRX) after today's DOJ press conference. Maris said based on the comments additional charges against Valeant or former Valeant executives cannot be ruled out,
Maris commented, "Earlier in the day, a Valeant... More
Valeant Pharma (VRX) Off Lows as Charges Relate to Employee Fraud Versus Company Fraud
November 17, 2016 11:45 AM ESTValeant Pharma (NYSE: VRX) is bouncing off morning lows as the charges against former exec Gary Tanner and CEO the Philidor Andrew Davenport appear more related to individual fraud versus company fraud. Shares of VRX are down 2% after trading down 7%... More
Valeant Pharma (VRX) Comments on Philidor Criminal Complaint; Says Co., Former CEO/CFO Not Yet Charged
November 17, 2016 10:48 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) learned that a criminal complaint was filed in relation to Philidor. Gary Tanner and Andrew Davenport were charged in the matter. The company, former CEO, former CFO, and current executives have not been charged at this... More

